companies / ipremom-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 39,503,40039.5M | ○ |
|---|---|---|
| founded | null | |
| hq | Paterna, Valencia, Spain | |
| industry | unknown | |
| stage | null |
iPremom develops molecular blood tests for early diagnosis of pregnancy complications such as preeclampsia. It targets clinicians and expectant mothers needing early risk detection. Its differentiator is analyzing thousands of circulating molecules to flag risk before symptoms appear.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-04-01 | grant | 2,700,0002.7M | null | ○ |
LiteSpeed, WordPress 6.9.4, LiteSpeed Cache, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, imagesLoaded 4.1.4, PHP, Plesk, DoubleClick Floodlight, Contact Form 7 6.1.5, CookieYes
| fact | status | src |
|---|---|---|
| Grant, $2.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |